Series B funded biotechs expand hiring, Tenpoint Therapeutics raises $85M for eye-health pipeline

Companies that secured series B rounds this year are scaling up their staff, making them attractive targets for biopharma talent.

Tenpoint Therapeutics, based in Warren, New Jersey, announced an $85 million series B and is hiring as it pushes its vision-rejuvenation programs forward. Its lead product, Yuvezzi, received FDA approval earlier this year for presbyopia, while two additional candidates remain in preclinical development.

The funding round also includes a larger raise of $2.1 billion by a biotech partnered with Eli Lilly, Johnson & Johnson and Novartis, underscoring strong investor confidence. Professionals seeking growth-stage opportunities should consider these firms as they expand.